secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001437749-25-033348
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q3 2025 revenue $86k, GAAP net loss ($19.4M), cash $95.2M
---------------------------------------------------------------------------

- Revenue of $86k from limited market release of nPulse Vybrance system.
- GAAP net loss ($19.4M) vs ($12.7M) in Q3 2024; Non-GAAP net loss ($13.5M) vs ($9.4M).
- Cash $95.2M at Sep 30, 2025; operating cash burn $13.0M in Q3 2025.
- Enrolled 40% of subjects in PRECISE-BTN thyroid nodule study; FDA IDE approved for NANOCLAMP AF surgical trial.
- Treated 150 patients with nsPFA 360° catheter in European AF feasibility study; IDE submission filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925033348/0001437749-25-033348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925033348/plse20250826_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer